Research Article
Evaluation of the Fracture Liaison Service within the Canadian Healthcare Setting
Table 2
Comorbidities, risk factors, and medications.
| | Comorbidities | FLS group | PCP group | value |
| | Diabetes, n (%) | 34 (15.1) | 18 (7.9) | 0.02 | | Lung disease, n (%) | 27 (12.0) | 31 (13.7) | 0.60 | | Liver disease, n (%) | 4 (1.8) | 5 (2.2) | 0.75 | | Chronic renal failure, n (%) | 13 (5.8) | 38 (16.7) | <0.001 | | Cardiovascular disease, n (%) | 111 (49.3) | 86 (37.9) | 0.01 | | Endocrine disorder, n (%) | 17 (7.6) | 40 (17.6) | 0.001 | | Inflammatory bowel disease, n (%) | 5 (2.2) | 11 (4.9) | 0.13 | | Celiac disease, n (%) | 1 (0.4) | 5 (2.2) | 0.10 | | Rheumatoid arthritis, n (%) | 1 (0.4) | 4 (1.8) | 0.18 | | Family history of cancer, n (%) | 107 (48.0) | 107 (47.1) | 0.86 | | Cancer/radiotherapy treatment, n (%) | 27 (12.0) | 35 (15.4) | 0.29 | | Vitamin D consumption, n (%) | 148 (65.8) | 197 (86.8) | <0.001 | | Mean (SD) dosage, IU/day | 2180.4 (5673.4) | 1837.7 (1447.8) | 0.42 | | Calcium consumption, n (%) (dietary and supp.) | 215 (95.6) | 217 (96.4) | 0.63 | | Dietary calcium consumption, n (%) | 533.7 (350.1) | 612.4 (382.0) | 0.03 | | Supplemental calcium consumption, n (%) | 62 (27.6) | 66 (29.1) | 0.72 | | Mean (SD) dosage, IU/day | 665.9 (394.9) | 822.0 (366.5) | 0.02 | | PPI use, n (%) | 60 (26.7) | 53 (23.4) | 0.42 | | SSRI/TCA use, n (%) | 48 (21.3) | 25 (11.0) | 0.003 | | Glucocorticoid usage, n (%) | 6 (2.7) | 15 (6.6) | 0.04 |
|
|
